Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.W | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by Infinityon Feb 16, 2023 9:15pm
151 Views
Post# 35291263

RE:RE:The real efficacy numbers

RE:RE:The real efficacy numbersEoga,  Those are impressive numbers by removing the 8 + 4 under treated patients or partially under treated.  Just curious,  would it not be better to simply isolate those 12 patients as a separate group and offer them the correct dosages.   If I were one of the 12 patients who got treated with a lower dosage,  I would happily accept the optimum dosage and hope for the best.  It will not muddy up the statistics, as long as those patients are fully informed and treated as a separate group for the purpose and re-evaluated after the optimum dosage.  We do understand that this is a Novel therapy and TLT erred on the side of caution or even a genuine mistake when calculating the bladder volume to decide on the dosage.   
<< Previous
Bullboard Posts
Next >>